ClinicalTrials.gg
CompletedNCT01948986Updated Feb 18, 2019Results posted

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

A Phase 1 interventional study of Ertugliflozin in Renal Impairment and Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.

Enrollment
9th of 32
36 · median 26
Started
2013
with 4 others
Phase 1
25 of 32
2 open now
Registered
16th of 32
by date

Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 9th largest by enrollment, is one of 5 that started in 2013, is one of 25 in phase 1, and was the 16th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Renal Insufficiency by Merck & Co., Inc, or all of them as a file.
02

Study summary

This is a study to evaluate the effect of renal impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and in healthy participants with normal renal function.

03

Conditions studied

  • Renal Impairment
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of approximately 18 to 40 kg/m\^2
  • Stable renal function
  • Male or female not of
  • Female of reproductive potential must agree or have their partner agree to use 2 acceptable methods of
  • Healthy subjects determined to be healthy by investigator screening
  • T2DM participants have a diagnosis of T2DM as per American Diabetes Association guidelines
  • T2DM participants to be on a stable anti-hyperglycemic regimen with no new drug or drug dosage within 8 weeks of study participation. Variations in daily dose of insulin up to 10% are permitted.

Exclusion criteria

Exclusion Criteria:

  • A positive urine drug screen for drugs of abuse or recreational drugs
  • Pregnant or nursing females
  • History of abuse of alcohol or illicit drugs
  • Significant renal or urinary disease within 6 months of study participation
  • History of within the past 5 years basal cell carcinoma of the skin or cervical cancer in situ
  • History of (HIV)
  • History of blood dyscrasias or any disorders causing hemolysis or unstable red blood cells
  • Any acute disease state (eg, , vomiting, fever, diarrhea) within 7 days before study participation
  • Treatment with an drug within 30 days of study participation
  • Use of herbal supplements within 28 days prior to study participation
  • Any malabsorption condition
  • Blood donation (excluding plasma donations) of approximately 1 pint within 56 days prior to study participation
  • History of sensitivity to ertugliflozin or other Sodium-Glucose co-Transporter 2 (SGLT2) inhibitors
  • History of sensitivity to heparin or heparin-induced thrombocytopenia
  • Unwilling or unable to comply with the study Lifestyle Guidelines
  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease including clinically relevant and significant drug allergies
  • Use of prescription drugs (hormonal methods of are allowed), vitamins and dietary supplements within 7 days of study participation
  • For T2DM participants, history of type 1 diabetes mellitus or a history of ketoacidosis
  • For T2DM participants, clinically significant abnormality
  • For T2DM participants, history of myocardial infarction, unstable angina, coronary revascularization, stroke or within 3 months of study participation
  • For T2DM participants, heart failure defined as Functional Class III-IV
  • For T2DM participants, renal allograft recipients
  • For T2DM participants, requiring dialysis
  • For T2DM participants, strict fluid restriction
  • For T2DM participants, urinary incontinence
  • For T2DM participants, acute renal disease
  • For T2DM participants, significant hepatic, cardiac, or pulmonary disease or clinically nephrotic
  • For T2DM participants, prescription and over-the-counter medication that is not taken according to a stable regimen for 7 days before study participation
  • For T2DM participants, on metformin should not be enrolled if their baseline renal function is outside the approved product labeling
  • For T2DM participants receiving any of the following medications within 7 days of study participation: 1. Other SGLT2 inhibitors (eg, dapagliflozin, canagliflozin, empagliflozin); 2. Other injectable anti-hyperglycemic agents including pramlintide or Glucagon-like peptide-1 (GLP-1) analogues; 3. Any drugs, including cyclosporine, tacrolimus, sirolimus; 4. Oral (note that inhaled, nasal and topical corticosteroids are permitted); 5. Any potent drug-metabolizing enzyme-inducing drug, including rifampin, phenytoin, and carbamazepine; 6. Probenecid, valproic acid, gemfibrozil.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Ertugliflozin 15 mg (T2DM with Normal Renal Function)

    Ertugliflozin (15 mg), oral, administered in participants with T2DM and with normal renal function

    Drug: Ertugliflozin

  • Experimental
    Ertugliflozin 15 mg (T2DM with Mild Renal Impairment)

    Ertugliflozin (15 mg), oral, administered in participants with T2DM and with mild renal impairment

    Drug: Ertugliflozin

  • Experimental
    Ertugliflozin 15 mg (T2DM with Moderate Renal Impairment)

    Ertugliflozin (15 mg), oral, administered in participants with T2DM and with moderate renal impairment

    Drug: Ertugliflozin

  • Experimental
    Ertugliflozin 15 mg (T2DM with Severe Renal Impairment)

    Ertugliflozin (15 mg), oral, administered in participants with T2DM and with severe renal impairment

    Drug: Ertugliflozin

  • Experimental
    Ertugliflozin, 15 mg (Healthy Part. with Normal Renal Funct.)

    Ertugliflozin (15 mg), oral, administered in participants with healthy participants and with normal renal function

    Drug: Ertugliflozin

Interventions

  • Single oral administration of 3 X 5 mg tablets.

    Also known as: MK-8835

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf)

    Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  2. Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  3. Apparent Clearance (CL/F) for Plasma Ertugliflozin

    CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  4. Maximum Observed Plasma Concentration (Cmax) for Ertugliflozin

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  5. Time for Cmax (Tmax) for Plasma Ertugliflozin

    Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  6. Terminal Half-Life (t1/2) for Plasma Ertugliflozin

    T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  7. Apparent Volume of Distribution Following Oral Administration (Vz/F) for Plasma Ertugliflozin

    VzF is the apparent volume of distribution during terminal phase after oral / extravascular administration. VzF = Dose/(AUCinf × kel) where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  8. Unbound Fraction (Fu) for Plasma Ertugliflozin

    Fraction of unbound (not protein-bound) drug in plasma. Fu is determined using in vitro equilibrium dialysis method: concentration in buffer at equilibrium/concentration in plasma at equilibrium. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  9. Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96)

    Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.

    Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1

  10. Percent of Dose Recovered Unchanged in Urine From 0 to 96 Hours Postdose (for Ertugliflozin Only) (Ae96%)

    Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96% = Ae96 / Dose × 100 Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.

    Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1

  11. Renal Clearance (CLr) for Urinary Ertugliflozin

    Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.

    Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1

  12. Number of Participants Who Experienced an Adverse Event (AE)

    An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 19 days

  13. Number of Participants Who Discontinued Study Due to an AE

    An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 5 days

  14. Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 Extrapolated to Infinite Time (AUCinf)

    Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  15. Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  16. Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06481944

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  17. Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06481944

    Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  18. Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06481944

    T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  19. Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06481944

    Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.

    Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1

  20. CLr for Urinary Glucuronide Metabolite PF-06481944

    Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.

    Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1

  21. Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 Extrapolated to Infinite Time (AUCinf)

    Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  22. Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  23. Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06685948

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  24. Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06685948

    Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  25. Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06685948

    T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.

    Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose

  26. Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06685948

    Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1

  27. Renal Clearance (CLr) for Urinary Glucuronide Metabolite PF-06685948

    Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

    Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1

  28. Change From Baseline in 24 Hour Inhibition of Glucose Reabsorption

    Inhibition of Glucose Reabsorption = 100 \* urinary glucose excretion / (eGFR(ML/MIN) \* Weighted Mean Plasma Glucose \* 0.0144). 0.0144 is a unit conversion factor used to make the ratio unitless. Geometric Coefficient of Variation was reported as a percent.

    Time frame: Baseline and 24 Hours

  29. Change From Baseline in 24 Hour Fluid Balance

    Fluid balance = fluid intake - urine output.

    Time frame: For 24 hours before Baseline (-48 to -24 hours) and up to 24 hours after dosing on Day 1 (Up to 24 hours)

Secondary outcomes

  1. Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin

    Participants were asked to void at the end of each prescribed interval with forced voids prior to start and at the end of each interval.

    Time frame: 0-4, 4-8, 8-12, 12-24 hours after dosing on Day 1

07

Results

Posted Feb 18, 2019

Participant flow

Participant flow — Overall Study
MilestoneErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Started68868
Completed68868
Not completed00000

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf)

Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ng•hr/mL
Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf)
ng•hr/mLErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf)1199 ± 421908 ± 282075 ± 191895 ± 231236 ± 27
Statistical analysis
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (heathy normal/t2dm normal): 103.07 · 90% CI 80.32 to 132.27The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (mild renal impair./pooled norm.): 156.34 · 90% CI 127.83 to 191.23The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (mod. renal impair./pooled norm.): 170.04 · 90% CI 139.02 to 207.98The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (severe renal impair./pooled norm.: 155.26 · 90% CI 124.38 to 193.80The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
PrimaryArea Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)

Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ng•hr/mL
Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
ng•hr/mLErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)1174 ± 421814 ± 272011 ± 181816 ± 231214 ± 27
Statistical analysis
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (heathy normal/t2dm normal): 103.42 · 90% CI 80.66 to 132.61The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (mild renal impair./pooled norm.): 151.63 · 90% CI 124.05 to 185.34The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (mod. renal impair./pooled norm.): 168.11 · 90% CI 137.53 to 205.49The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (severe renal impair./pooled norm.: 151.80 · 90% CI 121.69 to 189.36The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
PrimaryApparent Clearance (CL/F) for Plasma Ertugliflozin

CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · mL/min
Apparent Clearance (CL/F) for Plasma Ertugliflozin
mL/minErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Apparent Clearance (CL/F) for Plasma Ertugliflozin208.8 ± 42130.9 ± 28120.4 ± 19132.0 ± 23202.1 ± 27
PrimaryMaximum Observed Plasma Concentration (Cmax) for Ertugliflozin

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Ertugliflozin
ng/mLErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Maximum Observed Plasma Concentration (Cmax) for Ertugliflozin215.9 ± 35313.1 ± 30305.7 ± 23196.4 ± 28219.3 ± 26
Statistical analysis
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (heathy normal/t2dm normal): 101.57 · 90% CI 78.83 to 130.87The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (mild renal impair./pooled norm.): 143.74 · 90% CI 117.15 to 176.37The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (mod. renal impair./pooled norm.): 140.37 · 90% CI 114.40 to 172.23The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (severe renal impair./pooled norm.: 90.18 · 90% CI 71.99 to 112.96The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
PrimaryTime for Cmax (Tmax) for Plasma Ertugliflozin

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Median · Hours
Time for Cmax (Tmax) for Plasma Ertugliflozin
HoursErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Time for Cmax (Tmax) for Plasma Ertugliflozin1.00 (1.00 to 1.50)1.50 (1.00 to 2.00)1.50 (0.500 to 2.00)1.51 (0.500 to 3.02)1.00 (1.00 to 2.00)
PrimaryTerminal Half-Life (t1/2) for Plasma Ertugliflozin

T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · Hours
Terminal Half-Life (t1/2) for Plasma Ertugliflozin
HoursErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Terminal Half-Life (t1/2) for Plasma Ertugliflozin14.62 ± 6.3725.94 ± 13.9822.89 ± 7.3524.17 ± 5.9817.71 ± 3.53
PrimaryApparent Volume of Distribution Following Oral Administration (Vz/F) for Plasma Ertugliflozin

VzF is the apparent volume of distribution during terminal phase after oral / extravascular administration. VzF = Dose/(AUCinf × kel) where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution Following Oral Administration (Vz/F) for Plasma Ertugliflozin
LitersErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Apparent Volume of Distribution Following Oral Administration (Vz/F) for Plasma Ertugliflozin239.7 ± 53254.5 ± 50228.3 ± 27268.8 ± 41304.5 ± 39
PrimaryUnbound Fraction (Fu) for Plasma Ertugliflozin

Fraction of unbound (not protein-bound) drug in plasma. Fu is determined using in vitro equilibrium dialysis method: concentration in buffer at equilibrium/concentration in plasma at equilibrium. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · Percent of Unbound Drug
Unbound Fraction (Fu) for Plasma Ertugliflozin
Percent of Unbound DrugErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Unbound Fraction (Fu) for Plasma Ertugliflozin0.03437 ± 0.00112190.03458 ± 0.00276960.03804 ± 0.00212870.04107 ± 0.00366210.03484 ± 0.0014822
PrimaryCumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96)

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.

Time frame:
0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Reported as:
Geometric mean · Milligrams
Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96)
MilligramsErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96)0.1494 ± 550.1081 ± 540.09682 ± 210.05843 ± 400.1231 ± 48
PrimaryPercent of Dose Recovered Unchanged in Urine From 0 to 96 Hours Postdose (for Ertugliflozin Only) (Ae96%)

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96% = Ae96 / Dose × 100 Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.

Time frame:
0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Reported as:
Geometric mean · Percent
Percent of Dose Recovered Unchanged in Urine From 0 to 96 Hours Postdose (for Ertugliflozin Only) (Ae96%)
PercentErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Percent of Dose Recovered Unchanged in Urine From 0 to 96 Hours Postdose (for Ertugliflozin Only) (Ae96%)0.9952 ± 550.7200 ± 540.6456 ± 210.3893 ± 400.8213 ± 48
PrimaryRenal Clearance (CLr) for Urinary Ertugliflozin

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.

Time frame:
0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Reported as:
Geometric mean · mL/min
Renal Clearance (CLr) for Urinary Ertugliflozin
mL/minErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Renal Clearance (CLr) for Urinary Ertugliflozin2.092 ± 280.9872 ± 450.8024 ± 340.5360 ± 231.682 ± 33
Statistical analysis
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (heathy normal/t2dm normal): 80.39 · 90% CI 59.41 to 108.76The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (mild renal impair./pooled norm.): 53.46 · 90% CI 41.64 to 68.63The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (mod. renal impair./pooled norm.): 43.45 · 90% CI 33.85 to 55.78The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
  • Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) vs Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) · Ratio (severe renal impair./pooled norm.: 29.02 · 90% CI 22.04 to 38.21The model was an ANOVA model with renal function group as a fixed effect. The ratios (and 90% CIs) are expressed as percentages.
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 19 days
Reported as:
Number · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Number of Participants Who Experienced an Adverse Event (AE)12234
PrimaryNumber of Participants Who Discontinued Study Due to an AE

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 5 days
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Due to an AE
ParticipantsErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Number of Participants Who Discontinued Study Due to an AE00000
PrimaryArea Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 Extrapolated to Infinite Time (AUCinf)

Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ng•hr/mL
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 Extrapolated to Infinite Time (AUCinf)
ng•hr/mLErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 Extrapolated to Infinite Time (AUCinf)1559 ± 212620 ± 343668 ± 562742 ± 411113 ± 32
PrimaryArea Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)

Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ng•hr/mL
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
ng•hr/mLErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)1536 ± 212517 ± 323552 ± 552642 ± 401090 ± 33
PrimaryMaximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06481944

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06481944
ng/mLErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06481944217.8 ± 18309.0 ± 30358.5 ± 28218.6 ± 33168.6 ± 34
PrimaryTime for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06481944

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Median · Hours
Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06481944
HoursErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-064819442.00 (1.00 to 3.00)2.00 (1.50 to 4.00)3.00 (1.50 to 3.00)3.00 (1.50 to 4.00)2.00 (1.50 to 3.00)
PrimaryTerminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06481944

T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · Hours
Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06481944
HoursErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-0648194416.68 ± 9.4622.04 ± 12.1523.33 ± 6.1522.83 ± 5.9217.51 ± 5.69
PrimaryCumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06481944

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.

Time frame:
0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Reported as:
Geometric mean · Milligrams
Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06481944
MilligramsErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-064819447.056 ± 325.861 ± 363.768 ± 401.630 ± 416.225 ± 32
PrimaryCLr for Urinary Glucuronide Metabolite PF-06481944

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.

Time frame:
0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Reported as:
Geometric mean · mL/min.
CLr for Urinary Glucuronide Metabolite PF-06481944
mL/min.Ertugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
CLr for Urinary Glucuronide Metabolite PF-0648194476.28 ± 2438.73 ± 5817.67 ± 5610.27 ± 8094.53 ± 25
PrimaryArea Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 Extrapolated to Infinite Time (AUCinf)

Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ng•hr/mL
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 Extrapolated to Infinite Time (AUCinf)
ng•hr/mLErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 Extrapolated to Infinite Time (AUCinf)383.9 ± 26604.1 ± 39950.9 ± 75975.0 ± 53337.6 ± 27
PrimaryArea Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)

Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ng•hr/mL
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
ng•hr/mLErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)371.9 ± 27579.8 ± 37917.7 ± 74922.1 ± 51329.1 ± 28
PrimaryMaximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06685948

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06685948
ng/mLErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-0668594844.44 ± 2253.56 ± 1763.10 ± 4246.42 ± 3543.90 ± 24
PrimaryTime for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06685948

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Median · Hours
Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06685948
HoursErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-066859482.00 (1.50 to 3.00)3.00 (2.00 to 4.03)4.00 (2.00 to 4.00)3.51 (3.00 to 4.02)2.00 (2.00 to 3.00)
PrimaryTerminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06685948

T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.

Time frame:
Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · Hours
Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06685948
HoursErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-0668594814.87 ± 7.7721.71 ± 11.2622.49 ± 5.3025.22 ± 10.4215.68 ± 4.66
PrimaryCumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06685948

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Reported as:
Geometric mean · Milligrams
Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06685948
MilligramsErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-066859480.9575 ± 450.7882 ± 330.6603 ± 490.3195 ± 430.8287 ± 40
PrimaryRenal Clearance (CLr) for Urinary Glucuronide Metabolite PF-06685948

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

Time frame:
0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Reported as:
Geometric mean · mL/min
Renal Clearance (CLr) for Urinary Glucuronide Metabolite PF-06685948
mL/minErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Renal Clearance (CLr) for Urinary Glucuronide Metabolite PF-0668594841.82 ± 2422.50 ± 4511.95 ± 495.778 ± 4341.42 ± 31
PrimaryChange From Baseline in 24 Hour Inhibition of Glucose Reabsorption

Inhibition of Glucose Reabsorption = 100 \* urinary glucose excretion / (eGFR(ML/MIN) \* Weighted Mean Plasma Glucose \* 0.0144). 0.0144 is a unit conversion factor used to make the ratio unitless. Geometric Coefficient of Variation was reported as a percent.

Time frame:
Baseline and 24 Hours
Reported as:
Geometric mean · Percentage
Change From Baseline in 24 Hour Inhibition of Glucose Reabsorption
PercentageErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Change From Baseline in 24 Hour Inhibition of Glucose Reabsorption33.34 ± 2225.58 ± 7728.84 ± 3424.25 ± 6129.19 ± 34
Statistical analysis
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) · Ratio: mild ren. impa./t2dm norm. renal: 76.73 · 95% CI 48.58 to 121.19Adjusted geometrics mean values were used. The model was an ANOVA model with renal function group as a fixed effect.
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) · Ratio: mod. ren. impa./t2dm norm. renal: 86.52 · 95% CI 54.78 to 136.65Adjusted geometrics mean values were used. The model was an ANOVA model with renal function group as a fixed effect.
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) · Ratio: sev. ren. impa./t2dm norm. renal: 72.74 · 95% CI 44.63 to 118.58Adjusted geometrics mean values were used. The model was an ANOVA model with renal function group as a fixed effect.
PrimaryChange From Baseline in 24 Hour Fluid Balance

Fluid balance = fluid intake - urine output.

Time frame:
For 24 hours before Baseline (-48 to -24 hours) and up to 24 hours after dosing on Day 1 (Up to 24 hours)
Reported as:
Mean · Milliliters
Change From Baseline in 24 Hour Fluid Balance
MillilitersErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Change From Baseline in 24 Hour Fluid Balance-660.67 ± 515.48-937.00 ± 539.14-696.38 ± 832.57111.50 ± 736.79-478.63 ± 583.02
SecondaryUrinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin

Participants were asked to void at the end of each prescribed interval with forced voids prior to start and at the end of each interval.

Time frame:
0-4, 4-8, 8-12, 12-24 hours after dosing on Day 1
Reported as:
Geometric mean · Grams
Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin
GramsErtugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)
Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin72.31 ± 3035.98 ± 11327.55 ± 6810.09 ± 5746.33 ± 31
Statistical analysis
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) · Ratio (mild renal impair./t2dm norm. ren: 49.75 · 90% CI 27.22 to 90.93The model was an ANOVA model with renal function group as a fixed effect.
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) · Ratio (mod. renal impair./t2dm norm. ren: 38.10 · 90% CI 20.85 to 69.64The model was an ANOVA model with renal function group as a fixed effect.
  • Ertugliflozin 15 mg (T2DM With Normal Renal Function) vs Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) · Ratio (sev. renal impair./t2dm norm. ren: 13.95 · 90% CI 7.32 to 26.58The model was an ANOVA model with renal function group as a fixed effect.

Adverse events

Collected over Up to 19 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T2DM Normal Renal Function—0/6 (0%)1/6 (16.7%)
T2DM Mild Renal Impairment—0/8 (0%)2/8 (25%)
T2DM Moderate Renal Impairment—0/8 (0%)1/8 (12.5%)
T2DM Severe Renal Impairment—0/6 (0%)3/6 (50%)
Healthy Normal Renal Function—0/8 (0%)4/8 (50%)
Most frequent other events
Most frequent other events
EventT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal ImpairmentHealthy Normal Renal Function
HypoglycaemiaMetabolism and nutrition disorders0/61/80/82/60/8
Catheter site erythemaGeneral disorders1/60/80/80/60/8
Dermatitis contactSkin and subcutaneous tissue disorders0/60/80/81/61/8
ConstipationGastrointestinal disorders0/60/80/80/61/8
Vessel puncture site haemorrhageGeneral disorders0/61/80/80/60/8
Urinary tract infectionInfections and infestations0/60/81/80/60/8
Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders0/60/81/80/60/8
EcchymosisSkin and subcutaneous tissue disorders0/60/80/80/61/8
Rash papularSkin and subcutaneous tissue disorders0/60/80/80/61/8

Baseline characteristics

Renal function groups were based on body surface area (BSA)-unnormalized estimated glomerular filtration rate (eGFR).

Age, Continuous
Age, Continuous(Years)Ertugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)Total
Mean63.2 ± 3.566.4 ± 2.465.8 ± 7.961.2 ± 10.364.3 ± 3.964.4 (60 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)Total
Female1540313
Male5346523
Baseline Urinary Glucose Excretion (UGE)
Baseline Urinary Glucose Excretion (UGE)(Grams)Ertugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)Total
Median8.2 ± 10.490.1 ± 10.210.2 ± 0.932.3 ± 3.440.1 ± 0.041.8 (0.0 to 29.0)
Baseline eGFR
Baseline eGFR(mL/min/1.73 m²)Ertugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)Total
Mean92.1 ± 14.1064.7 ± 7.5237.1 ± 6.9217.0 ± 7.5188.5 ± 11.6460.5 (6.8 to 115.0)
Baseline Inhibition of Glucose Readsorption
Baseline Inhibition of Glucose Readsorption(Percentage)Ertugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)Total
Median2.7 ± 3.450.1 ± 5.170.3 ± 1.053.3 ± 19.420.0 ± 0.021.1 (0.0 to 50.4)
Baseline Fluid Balance
Baseline Fluid Balance(Milliliters)Ertugliflozin 15 mg (T2DM With Normal Renal Function)Ertugliflozin 15 mg (T2DM With Mild Renal Impairment)Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment)Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment)Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function)Total
Median-644.0 ± 668.11-274.8 ± 570.44238.8 ± 763.10-267.5 ± 430.85-359.5 ± 693.65-243.1 (-1780.0 to 1055.0)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Sahasrabudhe V, Terra SG, Hickman A, Saur D, Shi H, O'Gorman M, Zhou Z, Cutler DL. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus. J Clin Pharmacol. 2017 Nov;57(11):1432-1443. doi: 10.1002/jcph.955. Epub 2017 Jul 13. PubMed 28703316 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗
  • Marshall JC, Liang Y, Sahasrabudhe V, Tensfeldt T, Fediuk DJ, Zhou S, Krishna R, Dawra VK, Wood LS, Sweeney K. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure. J Clin Pharmacol. 2021 Sep;61(9):1220-1231. doi: 10.1002/jcph.1866. Epub 2021 Jun 19. PubMed 33813736 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Oct 2014, 12 months.

Results were first posted in Feb 2019, 4 years 4 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 12 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2013
First posted
Sep 24, 2013
StartActual
Oct 1, 2013
Primary completionActual
Oct 6, 2014
CompletionActual
Oct 16, 2014
Results first posted
Feb 18, 2019
Last update
Feb 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01948986
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Sep 24, 2013
Start date
Oct 1, 2013
Primary completion
Oct 6, 2014
Completion
Oct 16, 2014
Results posted
Feb 18, 2019
Last update
Feb 18, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion